{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:21:04Z","timestamp":1787167264252,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The introduction of neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC) has led to complex tumor responses that challenge conventional pathological assessment. Thus, traditional endpoints such as major pathological response (MPR) and pathological complete response (pCR) may become insufficient to capture the full spectrum of immune-mediated changes. Indeed, these parameters were originally developed in the context of cytotoxic chemotherapy and may not reflect immune-mediated phenomena and stromal remodeling which can significantly alter the appearance of the tumor bed. As a result, MPR and pCR may underrepresent the true extent of biological response in patients treated with immunotherapy. This review outlines current limitations in morphologic evaluation and highlights the need for immune-adapted criteria. Furthermore, it explores the additional value of digital pathology and AI that offer objective and reproducible quantification of histologic features. Integrating these tools with radiologic and molecular data supports a multidimensional approach to response assessment, aiming to refine prognostication, guide adjuvant therapy, and ensure consistency in clinical trial designs.<\/jats:p>","DOI":"10.3389\/fonc.2026.1716992","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:35:00Z","timestamp":1770183300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Reframing tumor bed evaluation in non-small cell lung cancer: histopathological challenges and future directions in the era of neoadjuvant immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Federica","family":"Pezzuto","sequence":"first","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Faccioli","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar El","family":"Mnif","sequence":"additional","affiliation":[{"name":"Pathology Unit, Faculty of Medicine of Tunis, University of Tunis El Manar","place":["Tunis, Tunisia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maggioni","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lunardi","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fortarezza","sequence":"additional","affiliation":[{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Giraudo","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavon","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]},{"name":"Oncologia Medica 2, Institute of Oncology Veneto (IOV)","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padova","place":["Padova, Italy"]},{"name":"Oncologia Medica 2, Institute of Oncology Veneto (IOV)","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dell\u2019Amore","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova","place":["Padova, Italy"]},{"name":"University Hospital of Padova","place":["Padova, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S218321","article-title":"Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC","volume":"12","author":"Yi","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.radonc.2021.11.033","article-title":"Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: Clinical outcomes and theoretical results from an extended LQ and TCP model","volume":"167","author":"Ai","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"107249","DOI":"10.1016\/j.lungcan.2023.107249","article-title":"The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies","volume":"181","author":"Pezzuto","year":"2023","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1453232","article-title":"Whole slide image-based weakly supervised deep learning for predicting major pathological response in non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a multicenter, retrospective, cohort study","volume":"15","author":"Han","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-24-169","article-title":"Real-world retrospective study of anti-PD-1 antibody in combination with chemotherapy as a neoadjuvant treatment strategy for locally advanced resectable esophageal squamous cell carcinoma","volume":"16","author":"Liu","year":"2024","journal-title":"J Thorac Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-1685","article-title":"Efficacy and safety of immunoradiotherapy for advanced non-small cell lung cancer: a retrospective comparative cohort study","volume":"15","author":"Gao","year":"2023","journal-title":"J Thorac Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.009","article-title":"Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells","volume":"150","author":"Zeng","year":"2020","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000441","article-title":"Pathology of surgically resected lung cancers following neoadjuvant therapy","volume":"31","author":"Berezowska","year":"2024","journal-title":"Adv Anat Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.07.017","article-title":"International association for the study of lung cancer study of reproducibility in assessment of pathologic response in resected lung cancers after neoadjuvant therapy","volume":"18","author":"Dacic","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2023.01.027","article-title":"Salvage surgery for advanced lung adenocarcinoma after epidermal growth factor receptor tyrosine kinase inhibitor treatment","volume":"116","author":"Lin","year":"2023","journal-title":"Ann Thorac Surgery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02660","article-title":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non\u2013Small-Cell Lung Cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102166","DOI":"10.1016\/j.labinv.2024.102166","article-title":"Concordance of whole-slide imaging and conventional light microscopy for assessment of pathologic response following neoadjuvant therapy for lung cancer","volume":"105","author":"Deutsch","year":"2025","journal-title":"Lab Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1115156","article-title":"Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer","volume":"13","author":"Al\u00ec","year":"2023","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41698-020-00135-2","article-title":"Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes","volume":"4","author":"Ling","year":"2020","journal-title":"NPJ Precis Onc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.670","article-title":"Histological assessment and interobserver agreement in major pathologic response for non-small cell lung cancer with neoadjuvant therapy","volume":"57","author":"Kim","year":"2025","journal-title":"Cancer Res Treat"},{"key":"B19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/1078-0432.CCR-23-2457","article-title":"Objective analysis and clinical significance of the spatial tumor-infiltrating lymphocyte patterns in non\u2013small cell lung cancer","volume":"30","author":"Lopez de Rodas","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.5.1584","article-title":"Grading of tumor regression in non-small cell lung cancer : morphology and prognosis","volume":"120","author":"Junker","year":"2001","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.017","article-title":"Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma","volume":"14","author":"Qu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1394505","article-title":"Tertiary lymphoid structures: new immunotherapy biomarker","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13903","article-title":"Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy","volume":"12","author":"Cai","year":"2021","journal-title":"Thorac Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"104265","DOI":"10.1016\/j.ebiom.2022.104265","article-title":"Multi-scale characterization of tumor-draining lymph nodes in resectable lung cancer treated with neoadjuvant immune checkpoint inhibitors","volume":"84","author":"Yang","year":"2022","journal-title":"EBioMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27920","article-title":"Safety and efficacy of salvage surgery after treatment with immune-checkpoint adjuvant inhibitors for advanced non-small cell lung cancer: A multicentric study","volume":"131","author":"Schiavon","year":"2025","journal-title":"J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.02.009","article-title":"Neoadjuvant chemoimmunotherapy complicates subsequent surgical resection and adjuvant immunotherapy is preferable from the surgical standpoint","volume":"19","author":"Ugalde Figueroa","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"New Engl J Med N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100310","DOI":"10.1016\/j.jtocrr.2022.100310","article-title":"Assessing pathologic response in resected lung cancers: current standards, proposal for a novel pathologic response calculator tool, and challenges in practice. JTO clinical and research reports","volume":"3","author":"Saqi","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"24163","DOI":"10.1038\/s41598-024-75175-w","article-title":"Concordance in the estimation of tumor percentage in non-small cell lung cancer using digital pathology","volume":"14","author":"Carretero-Barrio","year":"2024","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100302","DOI":"10.1016\/j.modpat.2023.100302","article-title":"Deep learning for predicting effect of neoadjuvant therapies in non-small cell lung carcinomas with histologic images","volume":"36","author":"Terada","year":"2023","journal-title":"Mod Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004605","article-title":"Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells","volume":"10","author":"Noyes","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2931","article-title":"Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1716992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:35:01Z","timestamp":1770183301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1716992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":37,"alternative-id":["10.3389\/fonc.2026.1716992"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1716992","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1716992"}}